Verified July 2026 · Cited to primary sources
Peptides marketed for libido, arousal and sexual function, graded by human evidence and legal status. The honest answer: PT-141 (bremelanotide) is the only FDA-approved option, and the rest run from real human pilot data (kisspeptin) to research-only.
Evidence for this goal
PT-141 (bremelanotide, Grade A) is the only FDA-approved option, cleared for premenopausal low sexual desire. Kisspeptin (Grade C) has small human arousal studies. Oxytocin and gonadorelin are approved drugs used off-label here. Melanotan-2 (Grade D) does cause erections but carries a real melanoma concern, and we do not recommend it.
How to read this comparison
Compounds are listed alphabetically, not ranked for this goal. The overall grade reflects the evidence described in each record. Evidence for one condition, population or product form does not establish benefit for every use. Affiliate availability never changes a grade.
A historical FDA survey of compounded drugs found 31% failed standard potency testing. What is actually in the vial is a separate question from whether the compound works, and a rubric like this exists to keep the two apart. See the full A to F methodology →
Evidence scope: Gonadorelin is native human GnRH and was an FDA-approved human drug (Factrel, gonadorelin HCl, for pituitary diagnostic testing; Lutrepulse, gonadorelin acetate, for pulsatile fertility therapy). Decades of clinical use and pharmacology as the reference GnRH molecule put it at Grade A for its established endocrine actions. Honest caveat: the popular current use, preserving testicular size and fertility on TRT, is a compounded, off-label application; the Grade A rests on its identity as approved GnRH and its well-documented axis effects, not on large TRT-adjunct trials.
Sources: FDA human label: Factrel (gonadorelin hydrochloride) for injection, Wyeth/Ayerst, diagnostic pituitary gonadotrope evaluation (RxList reproduction of the prescribing information) · Gonadorelin regulatory and pharmacology overview (Wikipedia, sourced): GnRH decapeptide, Factrel/Lutrepulse history
Gonadorelin is identical to natural gonadotropin-releasing hormone, the decapeptide released by the hypothalamus. Given in short pulses it stimulates pituitary gonadotropes to secrete LH and FSH, which drive testosterone and sperm production in men and ovulation in women. Its half-life is only a few minutes, so pulsatile dosing mimics physiology, while continuous exposure paradoxically downregulates the axis.
A real, formerly FDA-approved hormone with clean pharmacology and a sensible modern role: keeping the testicular axis alive during TRT via a compounding-pharmacy prescription. Grade A for its endocrine actions. The main caveats are that its headline TRT use is off-label and compounded, dosing frequency matters a lot, and it belongs under clinician supervision with periodic labs.
See the evidence →Evidence scope: There are genuine, peer-reviewed randomized human trials, which puts kisspeptin well above animal-only compounds. But they are small crossover mechanism studies (roughly 32 completers each), used IV infusion, and measured brain-imaging and arousal signals rather than a durable real-world treatment endpoint. It is not approved for anything. Small positive human pilots with real RCT design but no approval and no large efficacy trial is the definition of Grade C.
Sources: Mills et al., Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With HSDD, JAMA Network Open 2023 (RCT, PMID 36735255) · Thurston et al., Effects of Kisspeptin Administration in Women With HSDD, JAMA Network Open 2022 (RCT, PMC)
Kisspeptin is the natural output of KISS1 neurons in the hypothalamus. It binds the KISS1R (GPR54) receptor on GnRH neurons and is the key upstream trigger for GnRH release, which in turn drives LH and FSH from the pituitary. Beyond the classic reproductive axis, human imaging work shows kisspeptin also modulates limbic brain regions tied to sexual arousal and attraction.
One of the more scientifically interesting research peptides here, with legitimate JAMA-published RCTs showing it can activate sexual-brain circuits in people with low desire. But it is early-stage, investigational, IV-delivered, and unapproved. Promising signal, not a product. Treat home use of research-labeled kisspeptin as unproven and unsupervised.
See the evidence →Evidence scope: Grade D: no FDA approval and no adequate efficacy RCT, only small early studies, sold illegally with documented harms (decision-tree rule 5 fired: no published human efficacy RCT). Do not confuse it with afamelanotide (Melanotan-1 / Scenesse), a different, more receptor-selective peptide that IS FDA-approved (2019) for a rare condition (erythropoietic protoporphyria). Melanotan-2 is not that drug and is not approved for anything.
Sources: FDA Warning Letter (Melanocorp, Inc.): Melanotan II marketed as an unapproved new drug for injectable tanning · Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report (PMC), documented pigmentary/systemic effects · FDA 503A bulks list (Melanotan II removed from Category 2; no legal compounding route) · Afamelanotide (SCENESSE), the FDA-APPROVED, distinct MC1R-selective peptide, for comparison · Cleveland Clinic, Why You Should Never Use Nasal Tanning Spray, with dermatologist Allison Vidimos, RPh, MD: melanotan II still requires UV exposure to work, and is illegal to sell in all fifty US states, the United Kingdom and Australia · Forbes, Tanning Influencers Push Barbie Peptide. Here Are Risks Of Melanotan, by Bruce Y. Lee, MD, MBA, August 7, 2026: melanoma reports, rhabdomyolysis with kidney failure, renal infarction, and a documented twenty two hour priapism
A non-selective melanocortin-receptor agonist that stimulates melanocytes to produce pigment (tanning), with off-target effects on appetite, sexual arousal and the cardiovascular system because it hits multiple melanocortin receptors.
Melanotan-2 (MT-2) is an unapproved "tanning" peptide with documented serious harms: melanoma and mole changes, priapism, nausea, blood-pressure changes and rhabdomyolysis have all been reported. Human evidence is Grade D and the safety flag is red. It is not the same as FDA-approved afamelanotide (Scenesse). There is no safe or legal way to buy it, and we do not recommend it.
See the evidence →Evidence scope: Oxytocin is FDA-approved (Pitocin, NDA 018261) for labor induction/augmentation and postpartum bleeding, with decades of obstetric use, so it is unambiguously Grade A for those indications. The important asterisk: the reasons people seek it out, bonding, trust, libido, and mood, are not approved uses, and the intranasal behavioral literature is mixed and often fails to replicate. Grade A reflects the approved obstetric drug, not the social-peptide reputation.
Sources: FDA prescribing label: PITOCIN (oxytocin injection, USP), NDA 018261 (DailyMed)
Oxytocin is a nine-amino-acid hormone made in the hypothalamus and released by the posterior pituitary. It binds oxytocin receptors on uterine smooth muscle to produce contractions and on breast myoepithelial cells to trigger milk let-down, which are its approved medical actions. Centrally it acts as a neuromodulator involved in social bonding, trust, and sexual behavior, which is the basis of the off-label interest, though central effects from peripheral dosing are far less certain.
A genuine FDA-approved hormone, but the approval is for labor and postpartum bleeding, not for bonding, trust, or libido. For its real medical use it is Grade A and hospital-controlled because of uterine and water-intoxication risks. For the social/sexual reputation driving consumer interest, the intranasal evidence is weak and inconsistent, and gray-market sprays are unregulated. Respect the gap between the drug and the mythology.
See the evidence →Evidence scope: Grade A: FDA-approved (Vyleesi, 2019) on two pivotal Phase 3 RCTs (rule 1 fired: FDA-approved for ≥1 indication). The honest caveat: the trials met their endpoints but the real-world effect on desire was modest, and approval is only for premenopausal-women HSDD, not the other uses it is sold for off-label.
Sources: Drugs@FDA: Vyleesi (bremelanotide) NDA 210557, approved June 2019 · Kingsberg et al., Obstet Gynecol 2019: bremelanotide RECONNECT Phase 3 RCTs (n=1,247)
Activates central melanocortin receptors (chiefly MC4R) in the brain to increase sexual desire and arousal. A centrally-acting libido peptide, not a vascular drug like the PDE5 inhibitors.
PT-141 (bremelanotide) is an FDA-approved drug, Vyleesi (2019), for HSDD in premenopausal women, so its evidence is Grade A. The honest caveats: the benefit on desire is modest, and the other uses it's sold for (men, nasal sprays) are off-label and unproven. Access it via a licensed provider, not gray-market vials.
See the evidence →| Peptide | Overall grade | Legal & safety | Typical cost | Verdict | |
|---|---|---|---|---|---|
| Gonadorelin (GnRH) Synthetic GnRH, the master hormone that tells the pituitary to make LH and FSH. It was an FDA-approved human drug and is now widely used in compounded men's-health protocols to keep the testicular axis running during TRT. | Grade A | See evidenceSee the evidence for Gonadorelin (GnRH) | |||
| Kisspeptin (Kisspeptin-54 / Kisspeptin-10) An investigational reproductive hormone that sits one step above GnRH. Real, well-designed human trials show it can boost sexual-brain activity and arousal, but it is research-only and delivered by IV infusion, not a peptide you buy and inject at home. | Grade C | See evidenceSee the evidence for Kisspeptin (Kisspeptin-54 / Kisspeptin-10) | |||
| Melanotan-2 (MT-2) The tanning peptide sold under the nicknames "Barbie peptide" and "Barbie drug", unapproved, with documented serious harms. Melanoma and mole changes, priapism, nausea, and rhabdomyolysis have all been reported. This is a safety page, not a recommendation. | Grade D | See evidenceSee the evidence for Melanotan-2 (MT-2) | |||
| Oxytocin A real FDA-approved hormone drug (as Pitocin) used in obstetrics for labor and postpartum bleeding. The social, bonding, and libido claims that make it popular are mostly extrapolated from small studies, not approved uses. | Grade A | See evidenceSee the evidence for Oxytocin | |||
| PT-141 An FDA-approved peptide drug, not a research chemical. Proven to raise sexual desire in premenopausal women, but the benefit is modest and the off-label hype outruns it. | Grade A | See evidenceSee the evidence for PT-141 |
Reading this table: Grades refer to each compound's stated evidence scope, not every use in this category. Legal status and Safety are separate badges; Verdict is the compound summary. Affiliate availability never changes a grade. Full methodology.
FAQ
PT-141 (bremelanotide) is the only FDA-approved option, cleared in 2019 for premenopausal women with low sexual desire (Grade A). It acts on melanocortin receptors in the brain, not the vascular system like Viagra. Kisspeptin (Grade C) has small human studies but is not approved.
Melanotan-2 causes spontaneous erections through its melanocortin activity, which is how PT-141 was later developed. But melanotan-2 is Grade D, unapproved, and linked to changing moles and a melanoma concern. We do not recommend it; PT-141 is the studied, approved version of the same mechanism.
No. Kisspeptin is investigational. Small crossover studies (roughly 30 participants each) show it can enhance sexual and emotional brain responses, which puts it at Grade C, but it has no FDA approval and no large trial.
Read the evidence
Before you buy anything
Other goals
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.